Oct. 16, 2024 - In an article on AstraZeneca’s Farxiga blockbuster drug, PharmaVoice references Citeline’s “Billion Dollar Blueprint: The Journey to Blockbuster Status” report
Oct. 5, 2024 - Citeline data are referenced in a Financial Times article on GLP-1 weight-loss drugs (subscription required)
Sept. 27, 2024 - In MedCity News , Summer Colling concurs with the prevailing belief that KarXT will not be a first-line treatment for schizophrenia
Sept. 27, 2024 - Senior analyst Summer Colling provides commentary on the schizophrenia treatment KarXT in C&EN
Sept. 16, 2024 - Nielsen Hobbs shared his predictions on the future of the BIOSECURE Act with PharmaVoice
Sept. 12, 2024 - Commentary from analyst Nielsen Hobbs on the BIOSECURE Act is featured in STAT's DC Diagnosis Newsletter
Aug. 30, 2024 - Pharmacy Times included commentary from Pam Spicer, therapy area director, on the current state of Alzheimer’s drugs coming to market and their potential impact on physicians and patients
Aug. 27, 2024 - Data from Trialtrove was included in a Financial Times (MUU: 36,500,000) article on the current landscape for oncology treatment (registration required)
Aug. 23, 2024 - Therapy Area Director Pam Spicer is featured in a Pharmacy Times “Pharmacy Focus” podcast on the current pipeline of Alzheimer’s drugs
Aug. 4, 2024 - Brian Yang’s commentary was included in an in-depth The Wire China article discussing Novo Nordisk’s Ozempic, the GLP-1 market in China, and the wider Chinese biopharma industry (subscription required)
June 21, 2024 - A MedCity News article cites both principal analyst Amanda Micklus and Citeline data regarding precedents for the Sarepta gene therapy approval
June 13, 2024 - Endpoints News cited Citeline figures on Lu-177 trials in an article warning of a shortage of lutetium(registration required)
June 5, 2024 – In its ASCO coverage, PharmaLive Daily Advantage
June 3, 2024 - Claire Riches is interviewed regarding her role as a woman leader in pharma on The Pharma Recruiter podcast
May 30, 2024 - Swiss national publication Swissinfo , part of the Swiss Broadcasting Corporation, included a graphic with Citeline data on AI dealmaking
May 17, 2024 — Life Science Sweden ran a dedicated analysis of the Annual Pharma R&D Review and its insights, including an interview with Ian Lloyd
May 8, 2024 — In an article in The Times , Dan Chancellor provides context for AstraZeneca's withdrawal of its COVID-19 vaccine. (subscription required)
May 2, 2024 — In
an article on Q1 earnings, MM&M featured commentary on Moderna from analyst Flora Mackay
Apr. 25, 2024 — Analyst Dana Gheorge is quoted in an Investor's Business Daily article on radiopharmaceuticals
Apr. 24, 2024 — As part of our quarterly earnings analyses, MM+M featured Joseph Jacob’s commentary
around Roche’s Q1 earnings
Mar. 30, 2024 — The Economist featured Citeline data on AI-related pharmaceutical expenditures in its
Technology Quarterly on healthcare and AI
Mar. 7, 2024 — David Ridley offers his insights in an article in The Economist on nootropics
Mar. 7, 2024 — New Scientist included a comment from Dan Chancellor on Novo Nordisk’s Phase I
trial readout for amycretin
Mar. 6, 2024 — Analyst Summer Colling is extensively quoted in PharmaVoice (19.7K+ UVM) around
schizophrenia treatment innovation
Feb. 26, 2024 — Analyst Khang Koang
is quoted in PharmaVoice in an article on the skyrocketing sales of diabetes and weight loss GLP-1
receptors
Feb. 21, 2024 — A
PharmaVoice article on biotechs to watch in 2024 uses data and quotes from Biomedtracker's forecasting
report
Feb. 15, 2024 — PharmaVoice quoted Therapy Area Director Pam Spicer in an article
on Biogen’s Q4 earnings
Feb. 15, 2024 — City A.M. included Dan Chancellor’s commentary on GSK’s acquisition of Aiolos
Bio
Feb. 13, 2024 — Khang Hoang, Citeline cardiovascular and metabolic and infectious diseases analyst, is quoted in
Drug Discovery & Development on additional indications for GLP-1s
Feb. 13, 2024 — Investor’s Business Daily included comments from analyst Pamela Spicer on Biogen's
Q4 earnings, focusing on the slow launch of Leqembi
Feb. 8, 2024 — UK business national This Is Money included healthcare analyst Summer Colling's
commentary on AstraZeneca earnings in its live business blog
Jan. 22, 2024 — In
a PharmaVoice article on a universal COVID vaccine, senior analyst Natasha Boliter shares her insights on
the logistical advantage of a combination COVID, RSV, and flu vaccine
Jan. 22, 2024 — PharmaVoice included commentary from Jake Mathon and Sheila Omondi around challenge
trials, as well as supporting data from Citeline
Jan. 5, 2024 — A
PharmaVoice article on the state of infectious disease featured comments from senior analysts Natasha
Boliter and Charlotte Holmes
Dec. 20, 2023 — In an article on blockbuster drugs, PharmaVoice included commentary from Dan Chancellor
and Sara LeFever, as well as Citeline and Evaluate data
Dec. 12, 2023 — Proactive Investors featured Dan Chancellor’s analysis in an article discussing the
significance of the AstraZeneca/Icosavax acquisition
Dec. 12, 2023 — This is Money included Dan Chancellor’s comments on AstraZeneca’s agreement
to purchase vaccine specialist Icosavax
Dec. 8, 2023 — PharmaVoice featured Citeline and Evaluate data with commentary from The Dedham
Group’s Jen Klarer around FDA approval of the CRISPR-based sickle-cell anemia treatment Casgevy
Dec. 6, 2023 — Endpoints News quoted analyst Xin Zhao on the UK government’s new voluntary program
for branded medicines pricing, access and growth (VPAG)
Dec. 4, 2023 — Chemical &
Engineering News included Fenwick Eckhardt’s comments in a comprehensive roundup of the largest
events and
breakthroughs in the pharma space in 2023
Dec. 4, 2023 — PharmaVoice featured Dan Chancellor's commentary on Pharma M&A
Nov. 28, 2023 — Patricia
Giglio, Director of Deals Intelligence, is quoted in a PharmaVoice article on the top 5 IPOs of 2023 in
biopharma
Nov. 27, 2023 — C&EN featured comments from Malcolm Spicer around the effectiveness of OTC cold
medications
Nov. 8, 2023 — Senior analyst Natasha Boliter is the sole expert quoted in a PharmaVoice article on
AstraZeneca’s self-administered flu vaccine
Nov. 7, 2023 — New Scientist featured Dana Gheorge’s comments on approval of the drug anastrozole
for breast cancer prevention
Nov. 2, 2023 — Investor’s Business Daily featured senior analyst Jeff Stevens’ commentary on
Moderna Q3 earnings
Nov. 2, 2023 — PharmaVoice included commentary from Dan Chancellor, Director of Thought Leadership,
regarding the pharmaceutical landscape in 2023
Nov. 1, 2023 — International Clinical Trials
interviewed Luca Parisi on AI in clinical trial settings and how it can be used in line with human involvement to
positively change all stages of drug development
Oct. 31, 2023 — Investor’s Business Daily included Zhyar Said’s commentary on Pfizer’s
Q3 earnings
Oct. 24, 2023 — Analyst Mille Gray is quoted exclusively in a PharmaNewsIntelligence article on the
breast cancer therapeutics market
Oct. 23, 2023 — Luca Parisi, Citeline Director of Clinical Analytics, was interviewed on the FUTRtech
podcast; he discusses how AI and data are revolutionizing drug development
Oct. 17, 2023 — Haley Quinn, Go To Market Director of Patient Engagement and Recruitment, advocated for better
rare disease trial design in ACRP's Clinical Researcher
Oct. 17, 2023 — Reuters included Ellie Davenport insights on Keytruda’s FDA nod for expanded use in
lung cancer
Sept. 29, 2023 — Dan Chancellor shared his insights in Investor’s Business
Daily
on how FDA approval of exa-cel would change future uptake for allogenic gene therapies
Sept. 22, 2023 — Dan Chancellor was quoted in MM+M on the expanded indication of
Jardiance for chronic kidney disease
Sept. 14, 2023 — In an article on the adoption of weight-loss drugs, Pharma
Manufacturing cited statistics from Citeline’s Pharmaprojects database
Sept. 11, 2023 — MM+M shared Dan Chancellor’s insight on the relationship between the Inflation
Reduction Act (IRA) and the recent pullback of DTC marketing budgets
Sept. 9, 2023 — The Guardian included Jeffrey Stevens’ comments and Evaluate forecasts on the
obesity drug Wegovy
Sept. 5, 2023 — PharmaVoice included commentary from Ellie Davenport on the Roche trial data
leak
Sept. 1, 2023 — Life Science Leader published an article by Dan Chancellor on addressing the
uncertainties of the IRA in biopharma
Aug. 10, 2023 — CNBC included commentary from Zhyar Said on Wegovy and Ozempic
Aug. 10, 2023 — Emma Wille is quoted in article on the potential impact of the FDA’s rejection of zuranolone
for MDD in Drug Discovery and Development
Aug. 10, 2023 — PharmaVoice featured Dan Chancellor’s commentary on biotech IPOs
Aug. 3, 2023 — Quartz quoted Nielsen Hobbs around the impact of the mifepristone ruling on the broader
pharmaceutical industry
July 26, 2023 — Finance and business publication Shares included Zhyar Said’s comment around
GSK’s Q2 earnings in in its expert view section
July 20, 2023 — Investor’s Business Daily featured commentary on J&J earnings from Zhyar
Said
July 20, 2023 — Coverage in CE&N around Donanemab Phase III results
July 17, 2023 — The Financial Times used Datamonitor Healthcare forecasts in its article covering
the release of Eli Lilly’s donanemab data
July 6, 2023 — The Washington Post quoted Pam Spicer on the rollout of Leqembi
July 1, 2023 — The
Motley Fool mentioned a Citeline report to make an assessment on Pfizer’s health as a company
June 25, 2023 — Coverage in C&EN (458.9K+ UVM) for Anna Osborne around cancer vaccines
June 20, 2023 — PharmaVoice quoted Bridget Silverman on the future of accelerated approvals at the
FDA
June 16, 2023 — C&EN featured commentary from Peter Chang on the Novartis acquisition of Chinook
June 9, 2023 — Coverage in Pharma Manufacturing in its three-part series around antibody-drug
conjugates, with our data cited throughout parts one and three
May 8, 2023 — PharmaVoice included Sara LaFever’s commentary on three key FDA approval trends
this year
May 8, 2023 — Reuters featured Citeline data in article on weight-loss drugs
May 4, 2023 — C&EN included Andrew McConaghie’s commentary around the FDA’s approval of
GSK’s RSV vaccine
May 3, 2023 — Citeline’s data on AI applications for biopharma companies was cited in
Pharmaphorum
May 2, 2023 — Zhyar
Said’s commentary was featured in Investor’s Business Daily around Pfizer’s Q1 earnings
results
April 13, 2023 — Citeline was mentioned in The Medicine Maker alongside data from Pharmaprojects around
drug R&D
April 7, 2023 — The Guardian featured Anna Osborne’s commentary on mRNA cancer vaccines
April 6, 2023 — C&EN included Jeffrey Stevens’ commentary around how GSK is beefing up its
infectious disease portfolio with an antifungal from firm Scynexi
March 28, 2023 — C&EN featured Pam Spicer’s commentary around Biogen’s ALS drug,
tofersen
March 7, 2023 — Mike Gallup and Ashley Schwalje shared a byline in Applied Clinical Trials , highlighting
the role data technology will play in transforming clinical trial design
March 2, 2023 — The Economist featured Dan Chancellor’s commentary on the current landscape for
obesity drugs
Feb. 23, 2023 — Investor's Business Daily included Zhyar Said’s commentary around Moderna’s
Q4 earnings announcement
Feb. 10, 2023 — C&EN featured Dan Chancellor’s commentary around Structure Therapeutics’
IPO
Feb. 3, 2023 — C&EN featured commentary from Pam Spicer on the biosimilars landscape
Feb. 1, 2023 — City A.M. shared commentary from Zhyar Said on GSK’s earnings
Jan. 30, 2023 — PharmaVoice included insights from Dan Chancellor on how the weight loss pharma space
will be realizing its potential with new high-dose GLP-1 agonists
Jan. 24, 2023 — Investor's Business Daily included Zhyar Said’s commentary following
J&J’s Q4 earnings announcement
Jan. 17, 2023 — PharmaVoice featured extensive insights from Amanda Micklus on the pharma M&A
Jan. 12, 2023 — C&EN included commentary from Sara LaFever on the JP Morgan Healthcare
Learn More About Citeline
